【摘要】：根據(jù)時(shí)下較為流行的低成本國(guó)家采購(gòu)概念，這篇論文主要從醫(yī)藥行業(yè)G公司一些被挑選的、真實(shí)的低成本國(guó)家采購(gòu)項(xiàng)目出發(fā)，結(jié)合相關(guān)供應(yīng)鏈管理理論工具，以及G公司現(xiàn)行的一些方法工具進(jìn)行推敲對(duì)比，并提出更為優(yōu)化的改進(jìn)方案。 第一章節(jié)中的背景研究主要分為二個(gè)部分。一是中國(guó)醫(yī)藥行業(yè)無(wú)論從整個(gè)行業(yè)總產(chǎn)值，還是行業(yè)利潤(rùn)率，或者是外資、合資企業(yè)持續(xù)投資三個(gè)方面來(lái)看都是向上趨勢(shì)。二是從幾個(gè)熱門低成本國(guó)家的綜合實(shí)力的比較中得出中國(guó)具有較高的優(yōu)勢(shì)。其次，介紹了本文的研究意義以及思路。 第二章節(jié)的理論綜述中明確對(duì)低成本國(guó)家采購(gòu)的定義及相關(guān)優(yōu)勢(shì)。不得不提的是在執(zhí)行低成本國(guó)家采購(gòu)項(xiàng)目時(shí)可能碰到的風(fēng)險(xiǎn)和相應(yīng)解決方案以及工具。其中著重介紹了以二維象限法為理論基礎(chǔ)的供應(yīng)商分類法，以關(guān)鍵績(jī)效指標(biāo)法為理論基礎(chǔ)的供應(yīng)商質(zhì)量管理法，以及總擁有成本（TCO）等等對(duì)低成本國(guó)家采購(gòu)有著直接影響的理論工具。 第三章節(jié)就G公司的實(shí)際情況介紹分析了實(shí)際低成本國(guó)家采購(gòu)執(zhí)行中所碰到的問(wèn)題。 第四章節(jié)針對(duì)第三章中提出的問(wèn)題進(jìn)行了分析建議，提出合理化改進(jìn)方案。 第五章節(jié)對(duì)目前碰到問(wèn)題以外潛在存在的問(wèn)題，尤其是對(duì)將來(lái)會(huì)對(duì)可持續(xù)發(fā)展造成瓶頸的問(wèn)題進(jìn)行了提煉總結(jié)。 第六章節(jié)對(duì)以上五個(gè)章節(jié)做了大致的概括總結(jié)。 全文立足于中國(guó)醫(yī)藥行業(yè)大環(huán)境下，，針對(duì)G公司實(shí)際執(zhí)行的低成本國(guó)家采購(gòu)項(xiàng)目所產(chǎn)生的問(wèn)題，具體問(wèn)題具體分析，最終提出優(yōu)化方案。因?yàn)檎撐难芯繒r(shí)間較短，有部分不夠深入的地方已在第五章所提出的一些潛在挑戰(zhàn)中進(jìn)行概括，仍然需要今后在實(shí)際工作中更多地研究分析和驗(yàn)證。
[Abstract]:According to the current popular concept of low-cost country procurement, this paper mainly starts from some selected and real low-cost country procurement projects in pharmaceutical industry company G, combining with relevant supply chain management theory tools. And some existing methods and tools of G Company are compared, and a more optimized improvement scheme is put forward. The background research in the first chapter is divided into two parts. One is that the Chinese pharmaceutical industry is an upward trend in terms of the total output value of the whole industry, the profit margin of the industry, or foreign investment, and the sustained investment of the joint venture. Second, from the comparison of the comprehensive strength of several popular low-cost countries, China has a higher advantage. Secondly, this paper introduces the significance of the research and ideas. The second chapter makes clear the definition of low-cost country procurement and its relative advantages. Mention must be made of the risks and solutions and tools involved in the implementation of low-cost country procurement projects. The supplier classification method based on the two-dimensional quadrant method and the supplier quality management method based on the key performance index method are introduced. And total cost of ownership (TCO) and other theoretical tools that have a direct impact on low-cost country procurement. The third chapter introduces the actual situation of company G and analyzes the problems encountered in the actual low-cost country procurement execution. The fourth chapter analyzes the problems in the third chapter and puts forward the rationalization scheme. The fifth chapter summarizes the potential problems beyond the current problems, especially the problems that will lead to the bottleneck of sustainable development in the future. The sixth chapter makes a general summary of the above five chapters. This paper is based on the Chinese pharmaceutical industry environment, aiming at the problems caused by the low cost national procurement projects actually carried out by company G, the specific problems are analyzed, and the optimization scheme is finally put forward. Because the research time of the thesis is short and some parts of the research have been summarized in some potential challenges raised in Chapter 5, more research, analysis and verification are still needed in practical work in the future.
【學(xué)位授予單位】：上海外國(guó)語(yǔ)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F274;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 趙崎;;低成本國(guó)家采購(gòu)對(duì)中國(guó)供應(yīng)商的挑戰(zhàn)[J];國(guó)際市場(chǎng);2006年10期

本文編號(hào)：2198613